Institutional Repository UDD

Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania

Show simple item record

dc.contributor.author Frye, Mark
dc.contributor.author McElroy, Susan
dc.contributor.author Prieto, Miguel
dc.contributor.author Harper, Kelly
dc.contributor.author Walker, Denise
dc.contributor.author Kung, Simon
dc.contributor.author Chauhan, Mohit
dc.contributor.author Crow, Scott
dc.contributor.author Sutor, Bruce
dc.contributor.author Galardy, Christine
dc.contributor.author Veldic, Marin
dc.contributor.author Palmer, Brian
dc.contributor.author Geske, Jennifer
dc.contributor.author Fuentes, Manuel
dc.contributor.author Cuellar-Barboza, Alfredo
dc.contributor.author Seymour, Lisa
dc.contributor.author Mori, Nicole
dc.contributor.author Biernacka, Joanna
dc.date.accessioned 2017-05-04T19:07:36Z
dc.date.available 2017-05-04T19:07:36Z
dc.date.issued 2015
dc.identifier.citation J Clin Psychiatry. 2015 Feb;76(2):174-80
dc.identifier.uri http://hdl.handle.net/11447/1191
dc.identifier.uri http://dx.doi.org/10.4088/JCP.14m09127
dc.description.abstract INTRODUCTION: Identifying clinical and genetic risk factors associated with antidepressant-induced mania (AIM) may improve individualized treatment strategies for bipolar depression. METHOD: From 2009 to 2012, bipolar depressed patients, confirmed by DSM-IV-TR-structured interview, were screened for AIM. An AIM+ case was defined as a manic/hypomanic episode within 60 days of starting or changing dose of antidepressant, while an AIM- control was defined as an adequate (≥ 60 days) exposure to an antidepressant with no associated manic/hypomanic episode. 591 subjects (205 AIM+ and 386 AIM-) exposed to an antidepressant and a subset of 545 subjects (191 AIM+ and 354 AIM-) treated with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) were used to evaluate the association of AIM with phenotypic clinical risk factors previously published. 295 white subjects (113 AIM+ cases, 182 AIM-controls) were genotyped for 3 SLC6A4 variants: the 5-HTTLPR, single nucleotide polymorphism (SNP) rs25531, and the intron 2 variable number of tandem repeats (VNTR). Tests of association with AIM were performed for each polymorphism and the haplotype. RESULTS: The only clinical risk factors associated with AIM in the overall and the SSRI + SNRI analysis was bipolar I subtype. The S allele of 5-HTTLPR was not significantly associated with AIM; however, a meta-analysis combining this sample with 5 prior studies provided marginal evidence of association (P = .059). The L-A-10 haplotype was associated with a reduced risk of AIM (P = .012). DISCUSSION: Narrowly defined, AIM appears to be at greatest risk for bipolar I patients. Our haplotype analysis of SLC6A4 suggests that future pharmacogenetic studies should not only focus on the SLC6A4 promotor variation but also investigate the role of other variants in the gene.
dc.format.extent 7
dc.language.iso en_US
dc.publisher Memphis, Tenn., Physicians Postgraduate Press
dc.subject Bipolar Disorder/chemically induced
dc.subject Bipolar Disorder/genetics
dc.subject Genetic Variation/genetics
dc.subject Serotonin Plasma Membrane Transport Proteins/genetics
dc.subject Serotonin Uptake Inhibitors/adverse effects
dc.title Clinical risk factors and serotonin transporter gene variants associated with antidepressant-induced mania
dc.type Artículo


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Browse

My Account